Profile data is unavailable for this security.
About the company
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
- Revenue in EUR (TTM)278.27m
- Net income in EUR-151.06m
- Incorporated1998
- Employees629.00
- LocationMorphoSys AGSemmelweisstr. 7PLANEGG 82152GermanyDEU
- Phone+49 89899270
- Fax+49 8 989927222
- Websitehttps://www.morphosys.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BRAIN Biotech AG | 53.84m | -6.76m | 123.66m | 307.00 | -- | 3.90 | -- | 2.30 | -0.3095 | -0.3095 | 2.46 | 1.45 | 0.7095 | -- | -- | 154,712.60 | -8.52 | -10.80 | -10.67 | -14.10 | 54.95 | 55.98 | -12.01 | -19.88 | -- | -11.60 | 0.00 | -- | 28.23 | 13.75 | -32.54 | -- | 41.35 | -- |
| Heidelberg Pharma AG | 18.51m | -19.70m | 216.62m | 102.00 | -- | 3.25 | -- | 11.70 | -0.5254 | -0.5254 | 0.4961 | 1.43 | 0.3027 | 1.76 | 17.48 | 181,509.00 | -32.22 | -51.65 | -49.60 | -73.51 | 74.73 | 47.30 | -106.42 | -216.54 | 2.98 | -28.41 | 0.1934 | -- | 958.04 | 57.67 | 24.62 | -- | 8.06 | -- |
| Northern Data AG | 16.38m | -84.26m | 285.55m | 162.00 | -- | 0.9944 | -- | 17.44 | -7.25 | -7.25 | 1.41 | 12.06 | -- | -- | -- | 101,094.80 | -- | 20.18 | -- | 33.16 | 37.20 | 50.93 | -514.48 | 85.77 | 0.301 | -0.5252 | 0.2519 | 0.00 | 1,059.28 | 485.60 | 440.81 | -- | -- | -- |
| MorphoSys AG | 278.27m | -151.06m | 514.51m | 629.00 | -- | 3.26 | -- | 1.85 | -4.43 | -4.43 | 8.15 | 4.61 | 0.1124 | 2.16 | 3.33 | 442,395.90 | -6.10 | -10.92 | -6.88 | -12.32 | 82.53 | 88.74 | -54.29 | -77.84 | 3.83 | -2.55 | 0.6832 | -- | 54.93 | 33.03 | 70.64 | -- | 2.98 | -- |
| Eckert & Zieglr Strahln und Mdzntchnk AG | 213.44m | 28.61m | 924.37m | 945.00 | 31.82 | 4.55 | 23.94 | 4.33 | 1.37 | 1.37 | 10.23 | 9.59 | 0.5951 | 2.44 | 6.11 | 246,463.00 | 8.11 | 8.38 | 9.60 | 10.13 | 49.67 | 47.84 | 13.62 | 12.77 | 2.34 | 53.28 | 0.1848 | 35.57 | 2.44 | 5.52 | 62.20 | 27.08 | 40.17 | 24.82 |
| Formycon AG | 38.98m | 76.73m | 1.07bn | 178.00 | 10.79 | 2.53 | 13.74 | 27.57 | 6.21 | 6.21 | 3.35 | 26.46 | 0.0871 | 61.10 | 2.47 | 227,935.70 | 17.17 | -6.59 | 17.81 | -7.39 | 31.97 | 29.53 | 197.04 | -8.86 | 2.12 | -- | 0.0456 | -- | 20.35 | 16.22 | -127.42 | -- | -2.05 | -- |
| Biotest AG | 516.10m | -32.49m | 1.47bn | 2.23k | -- | 2.25 | -- | 2.84 | -1.64 | -1.64 | 26.08 | 18.76 | 0.4474 | 1.45 | 3.37 | 231,642.70 | -2.74 | -2.63 | -3.05 | -2.98 | 24.18 | 25.66 | -6.12 | -6.16 | 2.50 | -1.18 | 0.6345 | -- | 0.097 | 6.42 | 50.01 | -- | -22.75 | -- |
| Dermapharm Holding SE | 1.02bn | 134.24m | 2.02bn | 2.56k | 15.05 | 3.81 | 8.66 | 1.98 | 2.50 | 2.50 | 19.05 | 9.87 | 0.7268 | 1.46 | 12.11 | 399,834.60 | 9.41 | 10.96 | 10.86 | 12.64 | 64.49 | 60.19 | 12.94 | 14.39 | 1.28 | 9.39 | 0.4924 | 40.52 | 8.68 | 17.01 | -35.95 | 45.47 | -12.19 | -- |
